The enzyme phenylethanolamine N-methyltransferase (PNMT) catalyses the biosynthesis of adrenaline, a neurotransmitter linked to the central control of blood pressure. As part of an ongoing international collaboration to develop PNMT inhibitors, we found that the enzyme conceals a cryptic binding site (1-2). This site is revealed upon binding inhibitors that are double the size of the physiological substrate. The changes in active site size and shape are brought about by unfavourable side-chain conformations and rigid-body helix motions, at a modest estimated energetic cost of 2-3 kcal/mol. Our findings further underline the importance of incorporating protein flexibility in structure-based inhibitor design studies, and raise the question of whether such sites are accessible through moderate affinity fragment screening approaches. To address this question, we implemented fragment-based screening by X-ray crystallography for PNMT. We used the ActiveSight library of 384 compounds and found that a number of fragments bind to the PNMT active site. These will now be elaborated to develop potent and selective PNMT inhibitors. Keywords: enzyme inhibitor drug design, structure-based drug design, binding enzyme inhibitors
